Latest Us Market News

Ovanti Limited is proposing to issue over 520 million free-attaching options to recent placement investors and its lead manager, exercisable at $0.025 and expiring in 2030, pending shareholder approval.

EBR Systems has locked in a three-year purchasing agreement with CHRISTUS Health, the ninth-largest US hospital network, to advance its WiSE CRT System's US rollout across 66 hospitals.

Serko Limited posted a 34% jump in total income to NZD 120.9 million for FY26, powered by strong Booking.com for Business growth and a full year of GetThere revenue. The company’s EBITDAFI surged 137%, while net loss narrowed. Serko.ai’s US closed beta marks a strategic pivot into AI-driven business travel.

American Tungsten & Antimony Ltd (ASX: AT4) has raised A$10 million through a strongly supported placement and secured a 40% Utah state tax credit, underpinning its strategy to develop a domestic US supply chain for tungsten and antimony ahead of a planned Nasdaq listing.

Jindalee Lithium has launched a non-renounceable entitlement offer priced at A$0.46 per share, including attaching options exercisable at A$0.60, aiming to raise capital by early June 2026.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

EBR Systems has landed a significant purchasing agreement with Advocate Health, the third-largest US non-profit health system, opening access for its WiSE wireless cardiac pacing technology across 69 hospitals in eight states.

Brambles has trimmed its FY26 profit outlook due to US pallet repair capacity issues, impacting earnings by about US$60 million. The company is investing in quality improvements and expanding repair capacity, while announcing a new US$400 million share buy-back reflecting confidence in its cash flow.

Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.